Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Observations

A Rare but Serious Side Effect of Levofloxacin

Hypoglycemia in a geriatric patient

  1. Mehmet Kanbay, MD1,
  2. Timucin Aydogan, MD2,
  3. Rifat Bozalan, MD2,
  4. Ayse Isik, MD2,
  5. Burak Uz, MD2,
  6. Arif Kaya, MD2 and
  7. Ali Akcay, MD1
  1. 1Department of Nephrology, Fatih University Faculty of Medicine, Ankara, Turkey
  2. 2Department of Internal Medicine, Fatih University Faculty of Medicine, Ankara, Turkey
  1. Address correspondence to Mehmet Kanbay, MD, 35 sokak 81/5 Oktay Apt., Bahcelievler, Ankara, Turkey. E-mail: drkanbay{at}yahoo.com
Diabetes Care 2006 Jul; 29(7): 1716-1717. https://doi.org/10.2337/dc06-0788
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Hypoglycemia in a geriatric patient

Drugs should always be considered in the differential diagnosis of hypoglycemia. Fluoroquinolones have rarely been associated with hypoglycemia (1,2). Levofloxacine, which belongs to the fluoroquinolone group of antibiotics, has previously been reported to cause hypoglycemia in only one patient who was also receiving oral antidiabetic drugs (2). Herein, we describe an elderly patient with hypoglycemia associated with levofloxacine therapy who did use oral antidiabetic drugs or insulin.

A 64-year-old female with type 2 diabetes treated only by diet was interned for urinary infection and pneumonia. She had no history of malabsorbtion or oral intolerance. The patient’s weight was 84 kg, and she was 157 cm tall (corresponding to a BMI of 34.1 kg/m2). Her current medications included coraspin, omeprazole, and atorvastatin. Cefuroxime 3 × 750 mg/day i.v. was started. During cefuroxime therapy, her blood glucose levels were within normal limits with diet. C-reactive protein level was not decreased. On the 3rd day of treatment, cefuroxime was replaced with levofloxacin (500 mg/day) because of unresponsiveness. During treatment with levofloxacin, the symptoms of diseases diminished significantly, but the patient complained of generalized weakness. On the 2nd day of levofloxacin therapy, the patient became lethargic and disoriented. Blood pressure was 126/72 mmHg, heart rate was 82 bpm and regular, and body temperature was normal. Meningial irritation signs were absent, and pupils were intermediate, symmetric, and reactive. Optic fundi were normal, and no focal neurologic deficit was detected. Other physical findings were unremarkable. Her blood glucose level was measured as 32 mg/dl. The simultaneous blood insulin level was 6.7 IU (normal range 5–25 IU). Other routine hematological and biochemical blood tests were within normal range. Electrocardiography was also normal. A 30% dextrose infusion was started, and the patient thereafter became fully conscious without any neurologic deficit. Although she did not take any insulin during dextrose infusion, her consequent blood glucose levels were measured as 54 and 62 mg/dl in the 1st and following the 4th h. On the 3rd day of levofloxacin treatment, another hypoglycemic episode was observed. During treatment with levofloxacin, she did not change her usual daily diet regimen. Levofloxacin was stopped, and we continued treatment with piperacillin tazobactam. No further episodes of hypoglycemia were observed during follow-up period.

The symptomatic hypoglycemia in our patient developed 1 day after initiating treatment with levofloxacin. Since no other apparent cause for hypoglycemia was found, levofloxacin was the most likely etiology of this dangerous and potentially fatal glucose abnormality. Levofloxacin is an increasingly popular broad-spectrum antibiotic. In general, it has an excellent safety profile and is considered safe in patients with penicillin or cephalosporin allergy (3). Published reports about adverse effects of flouroquinolones are available for ciprofloxacin, gatifloxacin, clinafloxacin, and only one case of levofloxacin (2,4,5).

The previously published reports about fluoroquinolone-associated hypoglycemia consisted of elderly patients with a history of type 2 diabetes, renal dysfunction, and receiving oral sulfonylureas (2,4). Our patient also had only diabetes. Consistent with most published case reports, the hypoglycemia in our patient was documented within 24 h of levofloxacin administration, and intravenous dextrose was required for correction of hypoglycemia. Other factors such as poor oral intake or renal dysfunction that could have contributed to the profound and prolonged hypoglycemia were not present in our patient. The mechanisms by which fluoroquinolones cause hypoglycemia are not fully understood. In one study, increased rat pancreatic islet cell insulin release was claimed to be the mechanism. This process was inhibited by drugs that antagonized adenosine triphosphate-sensitive K+ channels, suggesting that this channel is involved (6). Use of the Naranjo ADR Probability Scale (7) indicated a probable relationship between the adverse effect of hypoglycemia and levofloxacin therapy in this patient.

This case showed that even one dose of levofloxacin might be associated with significant and even fatal complications in geriatric patients without any previous renal dysfunction or impaired oral intake. To our knowledge, this is the first case of hypoglycemia related to levofloxacin in an elderly diabetic patient not using any oral antidiabetic drugs or insulin. The purpose of this letter is to caution physicians dealing with geriatric patients against the inappropriate use of flouroqunolones in these patients, especially in those with diabetes, since they may have a greater tendency to hypoglycemia. It might be important to monitor blood glucose levels early in the course of therapy.

Footnotes

  • DIABETES CARE

References

  1. ↵
    Brogan ES, Chalan MK: Gatifloxacin as a possible cause of serious postoperative hypoglycemia. Anesth Analg 101:635–636, 2005
    OpenUrlCrossRefPubMed
  2. ↵
    Friedrich LV, Dougherty R: Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 24:1807–1812, 2004
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Norrby SR, Lietman PS: Safety and tolerability of fluoroquinolones. Drugs 45(Suppl. 3):59–64, 1993
    OpenUrl
  4. ↵
    Whiteley MS, Worlding J, Patel S, Gibbs KB: Hypoglycemia in a diabetic patient, associated with ciprofloxacin therapy. Pract Diabetes 10:35, 1999
    OpenUrl
  5. ↵
    Welling L, Burke CL: Safety of clinafloxacin (CLX), a new fluoroquinolone antibiotic. Presented at the 39th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 26–29 September 1999.
  6. ↵
    Saraya A, Yokokura M, Gonoi T, Seino S: Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol497:111–117, 2004
  7. ↵
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245, 1981
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Diabetes Care: 29 (7)

In this Issue

July 2006, 29(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Rare but Serious Side Effect of Levofloxacin
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Rare but Serious Side Effect of Levofloxacin
Mehmet Kanbay, Timucin Aydogan, Rifat Bozalan, Ayse Isik, Burak Uz, Arif Kaya, Ali Akcay
Diabetes Care Jul 2006, 29 (7) 1716-1717; DOI: 10.2337/dc06-0788

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

A Rare but Serious Side Effect of Levofloxacin
Mehmet Kanbay, Timucin Aydogan, Rifat Bozalan, Ayse Isik, Burak Uz, Arif Kaya, Ali Akcay
Diabetes Care Jul 2006, 29 (7) 1716-1717; DOI: 10.2337/dc06-0788
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Weight Gain and Gestational Diabetes Mellitus Is a Sensitive Issue
  • Beneficial Effects of a 4-Week Exercise Program on Plasma Concentrations of Adhesion Molecules
  • Is Metformin Safe in Patients With Mild Renal Insufficiency?
Show more Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.